NCT06175949View on ClinicalTrials.gov

A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

July 31, 2024

Conditions
Inflammatory Bowel Disease
Interventions
DRUG

HRS-7085 Tablets

HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,

DRUG

HRS-7085 simulant

PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY